CompletedPhase 2

CML Treated With Bosutinib After Relapse

Spain30 participantsStarted 2015-05

Plain-language summary

Prospective, open label, multicenter, phase II study evaluating correlation of SNPs with efficacy and toxicity in patients treated with Bosutinib. A total of 50 patients with previously treated Ph+ chronic phase CML will be included in the study

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Absolute neutrophil count \> 1000/mm3 (\>1000 x109/L)
✓. Platelets ≥ 100,000/mm3 (\>100 x109/L)
✓. absent any platelet transfusions during the preceding 14 days.

What they're measuring

Safety measured as adverse event gradation

Timeframe: 2 years

Trial details

NCT IDNCT02445742

SponsorPETHEMA Foundation

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-12

View on ClinicalTrials.gov More Chronic Myeloblastic Leukaemia trials